Reduced Apela/APJ system expression in patients with pulmonary artery hypertension secondary to chronic obstructive pulmonary disease

被引:3
|
作者
Hu, Yuexin [1 ]
Zong, Yani [1 ]
Jin, Liangli [1 ]
Zou, Jue [2 ,3 ]
Wang, Zhi [1 ,3 ]
机构
[1] Nanjing Med Univ, Dept Cardiovasc Med, Affiliated Brain Hosp, Nanjing, Peoples R China
[2] Nanjing Med Univ, Dept Pathol, Affiliated Brain Hosp, Nanjing, Peoples R China
[3] Nanjing Med Univ, Dept Cardiol, Affiliated Brain Hosp, 264 Guangzhou Rd, Nanjing 210029, Peoples R China
来源
HEART & LUNG | 2023年 / 59卷
关键词
Apela; Apelin peptide jejunum; Chronic obstructive pulmonary disease; Pulmonary artery hypertension; APELIN; ENDOTHELIUM; ELABELA; CELLS; HEART; GENE;
D O I
10.1016/j.hrtlng.2023.01.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Pulmonary artery hypertension (PAH) is a common disease that seriously threatens human physical and mental health. Chronic obstructive pulmonary disease (COPD) is the main cause of secondary PAH. Objectives: This study observed the differential expression of the endogenous Apela/APJ system in COPD patients with or without PAH. Methods: A total of 69 COPD patients were enrolled, including 31 patients with PAH (COPD+PAH). Lung tissue from healthy controls, COPD patients, and COPD patients with PAH was used for RT-PCR and histological examination. Results: The serum level of endogenous Apela in COPD+PAH patients was significantly lower than those in the control and COPD groups. Correlation analysis showed that systolic pulmonary artery pressure in COPD+PAH patients was negatively correlated with the serum level of endogenous Apela (r =-0.3842, p < 0.05). The percentage of intima thickening and muscularization of pulmonary arterioles was increased in COPD+PAH patients, while the expression of Apela/APJ was decreased. Compared with the healthy controls and COPD patients, the expression of endothelial markers vWF and CD34 mRNA in the pulmonary arterioles in COPD +PAH patients decreased, while the expression of interstitial markers a-SMA and vimentin mRNA was up -regulated. Conclusion: The present study suggests that expression of the Apela/APJ system is decreased in PAH second-ary to COPD. The pathological changes involved in PAH secondary to COPD include thickening of the intima and muscularization of the pulmonary arterioles, as well as endothelial-to-mesenchymal transition. Corrective action targeting the diminished Apela/APJ system may be a promising therapeutic strategy for PAH in the future. (c) 2023 Elsevier Inc. All rights reserved.
引用
收藏
页码:8 / 15
页数:8
相关论文
共 50 条
  • [21] Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension in Patients With Chronic Obstructive Pulmonary Disease: A Note of Caution
    Cheng, Richard
    Conrad, Miles
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (03):
  • [22] Effect of Ivabradine on Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease
    Akhmetzyanova, E. Kh.
    Gainitdinova, V. V.
    Bakirov, A. B.
    Bogoroditskaya, O. A.
    Timershina, I. R.
    KARDIOLOGIYA, 2012, 52 (02) : 41 - 46
  • [23] Pulmonary hypertension associated with chronic obstructive lung disease and idiopathic pulmonary fibrosis
    Adir, Yochai
    Harari, Sergio
    CURRENT OPINION IN PULMONARY MEDICINE, 2014, 20 (05) : 414 - 420
  • [24] Role of Vasoactive Intestinal Peptide in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension
    Lacedonia, Donato
    Valerio, Giuseppe
    Palladino, Grazia Pia
    Carpagnano, Giovanna Elisiana
    Correale, Michele
    Di Biase, Matteo
    Barbaro, Maria Pia Foschino
    REJUVENATION RESEARCH, 2014, 17 (01) : 33 - 39
  • [25] Problems of Diagnosis and Treatment of Pulmonary Hypertension in Old Patients With Chronic Obstructive Pulmonary Disease
    Malykhin, F. T.
    Baturin, V. A.
    KARDIOLOGIYA, 2016, 56 (03) : 87 - 96
  • [26] Can FVC/DLCO predict pulmonary hypertension in patients with chronic obstructive pulmonary disease?
    Sagmen, S. Beyhan
    Fidan, A.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (18) : 6658 - 6664
  • [27] Pulmonary hypertension in patients with chronic obstructive pulmonary disease: Recent advances in pathophysiology and management
    Hida, Q
    Tun, Y
    Kikuchi, Y
    Okabe, S
    Shirato, K
    RESPIROLOGY, 2002, 7 (01) : 3 - 13
  • [28] Echocardiographical Evaluation of Mean Pulmonary Artery Pressure in Patients With Chronic Obstructive Pulmonary Disease
    Alekhin, M. N.
    Dukova, N. A.
    Zateishchikova, A. A.
    Kiselev, D. G.
    Shavrin, I. V.
    Privalov, D. V.
    Vtorushin, D. V.
    Sidorenko, B. A.
    Zateishchikov, D. A.
    KARDIOLOGIYA, 2010, 50 (09) : 41 - 46
  • [29] Increased pulmonary serotonin transporter in patients with chronic obstructive pulmonary disease who developed pulmonary hypertension
    Armin Frille
    Michael Rullmann
    Georg-Alexander Becker
    Marianne Patt
    Julia Luthardt
    Solveig Tiepolt
    Hubert Wirtz
    Osama Sabri
    Swen Hesse
    Hans-Juergen Seyfarth
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 1081 - 1092
  • [30] Effect of Alprostadil Combined with Rosuvastatin on Oxidative Stress, Inflammatory Response and Angiogenesis in Chronic Obstructive Pulmonary Disease Patients Complicated with Pulmonary Artery Hypertension
    Zhao, Daguo
    Du, Xianrong
    Bao, Hongju
    LATIN AMERICAN JOURNAL OF PHARMACY, 2021, 40 (08): : 1879 - 1885